TARGETED THERAPY, KINASE INHIBITOR
Verzenio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat advanced or metastatic breast cancer. Verzenio may be prescribed in combination with Faslodex (fulvestrant), or used as a stand-alone treatment (monotherapy) if tumors have progressed after endocrine therapy and chemotherapy. Verzenio is indicated in cases where tumors are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Verzenio is also referred to by its drug name, abemaciclib.
Verzenio is a member of a class of drugs called kinase inhibitors. Verzenio is believed to work by slowing the growth of tumors.
How do I take it?
Prescribing information states that Verzenio is taken twice daily with meals.
Verzenio comes in tablet form.
The FDA-approved label for Verzenio lists common side effects including headache, fatigue, infections, blood cell changes, nausea, vomiting, loss of appetite, diarrhea, and abdominal pain.
Rare but serious side effects listed for Verzenio include severe diarrhea, lung disease, liver damage, and venous thromboembolisms (blood clots in the veins). If taken by pregnant women, Verzenio can harm the fetus.
For more details about this treatment, visit:
Verzenio — Lilly USA